Third quarter results 2022 for Medistim ASA

Another strong quarter ending at MNOK 116.5 in sales (MNOK 102.1), up 14 %. YTD revenue ended at MNOK 350.1 (MNOK 314.5), up 11.3 %. Sales growth is driven by the USA with a currency neutral sales increase of 18.7 % for the quarter and 24.1 % YTD. The Vascular business segment grows at 26.7 % for the quarter and 36.0 % YTD. The imaging products grows at 44.1 % for the quarter and 47.9 %. YTD Currency neutral sales of own products increase 14.7 % for the quarter and 11.8 % YTD. Operating profit (EBIT) for the quarter ended at MNOK 34.0 (MNOK 25.1), an EBIT margin of 29.3% (24.6%). Operating profit YTD ended at MNOK 104.8 (MNOK 96.8), an EBIT margin of 29.9% (30.8%). New Guidelines from the European Society of Vascular Surgery (ESVS) recommending intraoperative ultrasound after Carotid Endareterectomy (CEA.